Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Jules Bordet Institute
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01834469CT.gov Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients | — | Completed | — | — | — |
NCT02032485CT.gov Near-Infrared Imaging of Peritoneal Carcinomatosis From Colorectal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peritoneal Carcinomatosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Indocyanine Green (this asset) | Jules Bordet Institute | P2 | B · 63 |
| Fluorouracilum | Ciusss de L'Est de l'Île de Montréal | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P3 | BB |
| Muamycin | H. Lee Moffitt Cancer Center and Research Institute | P4 | BB |
| Oxaliplatin | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | P3 | BB |
| Irinotecan | Catharina Ziekenhuis Eindhoven | P3 | BB |
| Capecitabine | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | P2/3 | BB |
| Sodium Thiosulfate | National Cancer Institute (NCI) | P2 | B |
| Radspherin | Oncoinvent Solutions AS | P2 | B |
+33 more in the Peritoneal Carcinomatosis cohort
Other indications for Indocyanine Green
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Endometrial Carcinoma | — | P4 | BB · 70 |
| Vulva Cancer | — | P4 | BB · 70 |
| Rectal Cancer | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- FluorouracilumCiusss de L'Est de l'Île de MontréalBB
- Cis-Diamminedichloroplatinum IiNational Cancer Institute (NCI)BB
- MuamycinH. Lee Moffitt Cancer Center and Research InstituteBB
- OxaliplatinDaping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityBB
- IrinotecanCatharina Ziekenhuis EindhovenBB
Citation
Floatz Terminal. Indocyanine Green in Peritoneal Carcinomatosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/indocyanine-green-peritoneal-carcinomatosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →